Factor VIII half life and clinical phenotype of severe hemophilia A

Haematologica

Volumn 90, Issue 4, 2005, Pages 494-498

  Van Dijk, Karin ^a   Van Der Bom, Johanna G ^a,b   Lenting, Peter J ^a   De Groot, Philip G ^a   Mauser Bunschoten, Eveline P ^a   Roosendaal, Goris ^a   Grobbee, Diederick E ^a   Van Den Berg, H Marijke ^a,c  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Factor VIII; Half life; Hemophilia; Phenotype

Indexed keywords

BLOOD CLOTTING FACTOR 8;

ADULT; ARTICLE; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG HALF LIFE; FEMALE; HEMARTHROSIS; HEMOPHILIA A; HEMOSTASIS; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; OUTCOMES RESEARCH; PHENOTYPE; PROPHYLAXIS; RARE DISEASE; RISK ASSESSMENT; SCORING SYSTEM;

ADULT; CHILD, PRESCHOOL; COHORT STUDIES; DRUG ADMINISTRATION SCHEDULE; FACTOR VIII; HALF-LIFE; HEMOPHILIA A; HUMANS;

EID: 17844380517     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Schramm W, Royal S, Kroner B, Berntorp E, Giangrande F, Ludlam C, et al. Clinical outcomes and resource utilization associated with haemophilia care in Europe. Haemophilia 2002;8:33-43.
2. Molho P, Rolland N, Lebrun T, Dirat G, Courpied JF, Croughs T. et al. Epidemiological survey of the orthopaedic status of severe haemophilia A and B patients in France. The French Study Group. Haemophilia 2000;6:23-32.
3. Aledort LM, Haschmeyer RH, Pettersson H. A longitudinal study of orthopaedic outcomes for severe factor-VIII-deficient haemophiliacs. The Orthopaedic Outcome Study Group. J Intern Med 1994;236:391-9.
4. Lofqvist T, Nilzson IM, Berntorp E, Pettersson H. Haemophilia prophylaxis in young patients: a long-term follow-up. J Intern Med 1997;241:395-400.
5. Van Den Berg HM, Fischer K, Mauser-Bunschoten EP, Beek FJ, Roosendaal G, van der Bom JG, et al. Long-term outcome of individualized prophylactic treatment of children with severe haemophilia. Br J Haematol 2001;112:561-5.
6. Nilsson IM, Berntorp E, Lofqvist T, Pettersson H. Twenty-five years' experience of prophylactic treatment in severe haemophilia A and B. J Intern Med 1992;232:25-32.
7. Fischer K, Astermark J, van der Bom JG, Ljung R, Berntorp E, Grobbee DE, et al. Prophylactic treatment for severe haemophilia: comparison of an intermediate-dose to a high-dose regimen. Haemophilia 2002;8:753-60.
8. Fijnvandraat K, Peters M, ten Cate JW. Inter-individual variation in half-life of infused recombinant factor VIII is related to pre-infusion von Willebrand factor antigen levels. Br J Haematol 1995;91:474-6.
9. Fischer K, van der Bom JG, Mauser-Bunschoten EP, Roosendaal G, Frejs R, Grobbee DE, et al. Changes in treatment strategies for severe haemophilia over the last 3 decades: effects on clotting factor consumption and arthropathy. Haemophilia 2001;7:446-52.
10. Pettersson H, Ahlberg A, Nilsson IM. A radiologic classification of hemophilic arthropathy. Clin Orthop 1980;2:153-9.
11. Fischer K, van der Bom JG, Prejs R, Mauser-Bunschoten EF, Roosendaal G, Grobbee DE, et al. Discontinuation of prophylactic therapy in severe haemophilia: incidence and effects on outcome. Haemophilia 2001;7:544-50.
12. Allain JP. Principles of in vivo recovery and survival studies of VIII:C. Scand J Haematol Suppl 1984;41:123-30.
13. Messori A, Longo G, Morfini M, Cinotti S, Filimberti E, Giustarini G, et al. Multivariate analysis of factors governing the pharmacokinetics of exogenous factor VIII in haemophiliacs. Eur J Clin Pharmacol 1988;35:663-8.
14. Longo G, Messori A, Morfini M, Baudo F, Ciavarella N, Cinotti S, et al. Evaluation of factor VIII pharmacokinetics in hemophilia-A subjects undergoing surgery and description of a nomogram for dosing calculations. Am J Hematol 1989;30:140-9.
15. Morfini M, Lee M, Messori A. The design and analysis of half-life and recovery studies for factor VIII and factor IX. Factor VIII/Factor IX Scientific and Standardization Committee of the International Society for Thrombosis and Haemostasis. Thromb Haemost 1991;66:384-6.
16. Verbruggen B, Novakova I, Wessels H, Boezeman J, van den Berg HM, Mauser-Bunschoten E. The Nijmegen modification of the Bethesda assay for factor VIII:LC inhibitors: improved specificity and reliability. Thromb Haemost 1995;73:247-51.
17. Kasper CK, Aledort L, Aronson D, Counts R, Edson JR, van Eys J, et al. Proceedings: a more uniform measurement of factor VIII inhibitors. Thromb Diath Haemorrh 1975;34:612.
18. Romijn RA, Westein E, Bouma BN, Schiphorst ME, Sixma JJ, Lenting PJ, et al. Mapping the collagen-binding site in the von Willebrand factor-A3 domain. J Biol Chem 2003;278:15035-9.
19. nd ed. London: Chapman & Hall. 1989.
20. Fischer K, van Hout BA, van der Bom JG, Grobbee DE, van den Berg HM. Association between joint bleeds and Pettersson scores in severe haemophilia. Acta Radiol 2002;43:528-32.
21. Batlle J, Gomez E, Rendal E, Torea J, Loures E, Couselo M, et al. Antibodies to factor VIII in plasma of patients with hemophilia A and normal subjects. Ann Hematol 1996;72:321-6.
22. Fijnvandraat K, Berntorp E, ten Gate JW, Johnsson H, Peters M, Savidge G, et al. Recombinant, B-domain deleted factor VIII (r-VIII SQ): pharmacokinetics and initial safety aspects in hemophilia A patients. Thromb Haemost 1997;77:298-302.
23. Messori A, Longo G, Matucci M, Morfini M, Ferrini PL. Clinical pharmacokinetics of factor VIII in patients with classic haemophilia. Clin Pharmacokinet 1987;13:365-80.
24. Kasper CK, Kim HC, Gomperts ED, Smith KJ, Salzman PM, Tipping D, et al. In vivo recovery and survival of monoclonal-antibody-purified factor VIII concentrates. Thromb Haemost 1991;66:730-3.
25. Matucci M, Messori A, Donati-Cori G, Longo G, Vannini S, Morfini M, et al. Kinetic evaluation of four Factor VIII concentrates by model-independent methods. Scand J Haematol 1985;34:22-8.
26. Vlot AJ, Mauser-Bunschoten EF, Zarkova AG, Haan E, Kruitwagen CL, Sixma JJ, et al. The half-life of infused factor VIII is shorter in hemophiliac patients with blood group O than in those with blood group A. Thromb Haemost 2000;83:65-9.